Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Average portfolio weight of all funds dedicated to VRTX is 0.51%, an increase of 5.07%. Total shares owned by institutions increased in the last three months by 1.10% to 287,243K shares.

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0 ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.